What does Steminent Biotherapeutics Inc. do?

Steminent Biotherapeutics Inc. (7729.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 7729.TWO's market cap?

Steminent Biotherapeutics Inc. (7729.TWO) has a market capitalization of approximately $5.77 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 7729.TWO pay a dividend?

No — Steminent Biotherapeutics Inc. (7729.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 7729.TWO profitable?

Steminent Biotherapeutics Inc. (7729.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

7729.TWO

Steminent Biotherapeutics Inc.

TWO·Biotechnology · Healthcare

NT$78.90NT$0.70+0.90%

Market capNT$5.77B·Aug 26 6:58 AM UTC

Price Chart

NT$78.90+NT$0.70 (+0.90%)today

+120.21%CAGR +37.86%

Select date range

FromTo

Mar 11, 2024Mar 11, 2024 → Aug 26, 2026· 2.5 yrsAug 26, 2026

Key Metrics

7729.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$204.46M

Net Margin—

Operating Cash Flow−NT$173.71M

Capital ExpendituresNT$5.12M

Free Cash Flow−NT$178.83M

Return on Equity−20.3%

Return on Invested Capital−10.5%

Net CashNT$822.03M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 7729.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 7729.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 7729.TWO and 80,000+ other tickers.

About Steminent Biotherapeutics Inc.

Steminent Biotherapeutics Inc. is a biopharmaceutical company dedicated to pioneering novel cellular therapeutics, with a primary focus on the research and development of innovative stem cell drugs. Their flagship product is Stemchymal, which is recognized for its significant therapeutic benefits and broad range of potential applications. The firm was established on December 18, 2007, and operates from its headquarters in Taipei, Taiwan.

CEO: Ling-Mei Wang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 55
Website: www.steminent.com

Peers

Gwo Xi Stem Cell Applied Technology Co. , Ltd

Cap

NT$1.8B

4168.TWO

GlycoNex Incorporation

Cap

NT$2.6B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 7729.TWO

What does Steminent Biotherapeutics Inc. do?: Steminent Biotherapeutics Inc. (7729.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 7729.TWO's market cap?: Steminent Biotherapeutics Inc. (7729.TWO) has a market capitalization of approximately $5.77 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 7729.TWO pay a dividend?: No — Steminent Biotherapeutics Inc. (7729.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 7729.TWO profitable?: Steminent Biotherapeutics Inc. (7729.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.